HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prostate health

This article was originally published in The Tan Sheet

Executive Summary

A combination of cernitin, saw palmetto, B-sitosterol and vitamin E, when taken for three months, can significantly lessen nocturia frequency and enhance overall prostate health while causing no adverse effects, Harry Preuss, MD, et al., Georgetown University Medical Center, conclude in an abstract presented at the annual meeting of the American College of Nutrition. In a randomized, double-blind trial, investigators studied 70 patients in the verum group and 57 in a placebo group, all of whom were diagnosed with benign prostatic hyperplasia and had no evidence of cancer. Subjects in the natural products group demonstrated significant decreases in nocturia and daytime frequency and greater improvement in total AUA Symptom Index scores compared to the placebo arm. PSA measurements, maximal and average urinary flow rates and residual volumes showed no statistically significant differences. Preuss previously has voiced support for a health claim petition for saw palmetto extract and symptoms of mild benign enlarged prostate (1"The Tan Sheet" May 31, p. 8)

You may also be interested in...

Health Claims Petitions Cite Favorable Risk/Benefit Ratio - GU Prof

Pending health claims petitions for dietary supplements containing vitamin E, saw palmetto, pysllium, and folic acid/vitamins B6 and B12 are based on "such a favorable risk/benefits ratio that the public should be given proper information concerning the potential benefits of these nutraceuticals," Harry Preuss, MD, Georgetown University Medical Center, maintained at a May 25 press conference on Capitol Hill.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts